Log in

Relevant bibliographies by topics / End of Treatment Response / Journal articles

To see the other types of publications on this topic, follow the link: End of Treatment Response.

Journal articles on the topic 'End of Treatment Response'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'End of Treatment Response.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ramachandiran, Sampath, Xiangxue Guo, Laurent Garderet, et al. "Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma." Blood 118, no. 21 (2011): 2891. http://dx.doi.org/10.1182/blood.v118.21.2891.2891.

Full text

Abstract:

Abstract Abstract 2891 The proteasome inhibitor, bortezomib, is a powerful agent for the treatment of Multiple Myeloma (MM). However, many patients fail to achieve an optimal response. To identify biomarkers that could predict an optimal response to bortezomib, we assessed the role of the noncanonical NF-kB pathway in the response to bortezomib. Our in vitro studies identified that NF-kB2/p100 protein levels correlated directly with bortezomib sensitivity. Based on this finding, we measured at diagnosis the mRNA levels of different NF-kB2 regions in 64 patients schedule to receive bortezomib-b

APA, Harvard, Vancouver, ISO, and other styles

2

Oh, Minyoung, Hyungwoo Cho, Ji Eun Park, et al. "A Comparative Study of [18f]FDG PET and MRI for Evaluating Treatment Response in Primary CNS Lymphoma Patients Undergoing High-Dose Methotrexate Therapy." Blood 144, Supplement 1 (2024): 4468. https://doi.org/10.1182/blood-2024-198351.

Full text

Abstract:

Introduction : The standard method for evaluating response in patients with primary central nervous system lymphoma (PCNSL) is T1-weighted contrast-enhanced brain magnetic resonance imaging (MRI). However, brain MRI has limitations in distinguishing between complete response (CR), radiologically unconfirmed complete response (CRu), and partial response (PR) when evaluating treatment responses to predict clinical outcomes. We have previously reported on the role of 18F-fluorodeoxyglucose brain positron emission tomography/computed tomography ([18F]FDG brain PET/CT) in prognostication and respon

APA, Harvard, Vancouver, ISO, and other styles

3

Pavletic, S. Z. "Response as an end point in treatment trials for acute GVHD." Bone Marrow Transplantation 47, no. 2 (2012): 161–63. http://dx.doi.org/10.1038/bmt.2011.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Levin, Phillip D., Charles L. Sprung, and Andrew E. Simor. "End-of-Life Treatment and Antibiotic Resistance Data Raise Questions: Response." Chest 138, no. 5 (2010): 1286. http://dx.doi.org/10.1378/chest.10-1720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Arunachalam, Ruckmani. "Evaluation of the Feasibility of using Urine IP-10 as a Biomarker to Assess the Treatment Response to the Pharmacotherapy of Active Pulmonary Tuberculosis in the Intensive and Continuation Phase." Journal of Communicable Diseases 54, no. 4 (2022): 36–40. http://dx.doi.org/10.24321/0019.5138.2022100.

Full text

Abstract:

Introduction: Tuberculosis is well known for its chronicity, treatment failures, and drug resistance. Interferon-gamma Inducible Protein 10 (INF IP-10) has been reported to be relatively specific for assessing the severity of tuberculosis, and it can be easily estimated in both urine and blood. Objective: To determine whether urinary IP-10 levels can be used as a biomarker for monitoring treatment response in patients with active Pulmonary Tuberculosis (PTb). Materials and Method: 40 participants were enrolled. Urine samples were collected at diagnosis, at the end of 1st, 2nd & 6 months. S

APA, Harvard, Vancouver, ISO, and other styles

6

Smith, J., K. Williams, S. Birkett, H. Nicholson, P. Glue, and D. J. Nutt. "Neuroendocrine and clinical effects of electroconvulsive therapy and their relationship to treatment outcome." Psychological Medicine 24, no. 3 (1994): 547–55. http://dx.doi.org/10.1017/s0033291700027707.

Full text

Abstract:

SynopsisTwo groups of variables, endocrine and clinical, have been reported to have predictive value in determining response to electroconvulsive therapy (ECT) in depressed patients. Baseline levels of oxytocin associated neurophysin (OAN) and peak OAN response to ECT may predict clinical outcome, while the presence of delusional symptoms may indicate favourable initial response to ECT. The purpose of this study was to examine the relationship between these variables on initial and longer term response over a course of ECT, using a direct measure of plasma oxytocin concentrations. A substantia

APA, Harvard, Vancouver, ISO, and other styles

7

Wierda, William G., Thomas J. Kipps, Michael J. Keating, et al. "Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease." Blood 112, no. 11 (2008): 2109. http://dx.doi.org/10.1182/blood.v112.11.2109.2109.

Full text

Abstract:

Abstract We conducted a phase II trial with alemtuzumab self-administered, subcutaneously (SQ) to eliminate residual disease after chemotherapy or chemoimmunotherapy for patients (pts) who were in partial remission (PR) or pts in complete remission (CR) with 2-color flow cytometry evidence of disease. Pts received alemtuzumab SQ 3mg, 10mg, 30mg on days 1,2,3 then 30mg thrice weekly for a total of 12 doses, including rampup. After the 12th dose, pts with residual disease could receive a second course of 12 additional doses. Responding pts were pts in PR who converted to nodular PR (NPR) or CR b

APA, Harvard, Vancouver, ISO, and other styles

8

Drazilova, Sylvia, Martin Janicko, Pavol Kristian, et al. "Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia." Gastroenterology Research and Practice 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/8682494.

Full text

Abstract:

Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia.Methods. Retrospective evaluation of a cohort of all Roma patients treated with pegylated interferon alpha 2a from 2007 to 2013 in 3 centers for treatment of chronic viral hepatitis B. The Study included 43 Roma patients with chronic viral hepatitis B and randomly selected control group. Treatment duration was 48 weeks. Viral response was evaluated after 24 weeks, at the end of treatment, and 24 weeks

APA, Harvard, Vancouver, ISO, and other styles

9

Amir, Muhammad, Attiya Sabeen Rahman, Qaiser Jamal, and Muhammad Asadullah Siddiqui. "End treatment response and sustained viral response in hepatitis C virus genotype 3 among Pakistani population." Annals of Saudi Medicine 33, no. 6 (2013): 555–58. http://dx.doi.org/10.5144/0256-4947.2013.555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Castaldo, Matteo, Tiziana Atzori, Angela Comanducci, et al. "A Randomized, Double-Blind, Controlled Trial Protocol for Therapeutic Neuroscience Education in Chronic Migraine Patients: A Clinical–Neurophysiological Combined Study Design." Methods and Protocols 8, no. 2 (2025): 22. https://doi.org/10.3390/mps8020022.

Full text

Abstract:

Chronic migraine (CM) is a highly disabling condition, affecting about 2% of the global population. Non-pharmacological treatments can be optimal for their non-invasive nature. This prospective, randomized, double-blind, controlled trial aimed to test the efficacy of therapeutic neuroscience education (TNE) in CM. Early response biomarkers were also evaluated. A total of 80 CM patients were consecutively enrolled and randomly allocated to TNE or a general education program. Treatment effectiveness was evaluated at baseline (T1) and 2 months after the end of treatment (T4). We collected the res

APA, Harvard, Vancouver, ISO, and other styles

11

Jager, E., H. Bernard, and A. Knuth. "Palliative treatment for advanced gastrointestinal cancer: is response a suitable end-point?" Cancer Treatment Reviews 22 (January 1996): 113–15. http://dx.doi.org/10.1016/s0305-7372(96)90072-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, et al. "nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors." Journal of Clinical Oncology 39, no. 33 (2021): 3660–70. http://dx.doi.org/10.1200/jco.21.01728.

Full text

Abstract:

PURPOSE Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570 ). PATIENTS AND METHODS Patients with malignant PEComa were treated with nab-sirolimus 100 mg/m2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology

APA, Harvard, Vancouver, ISO, and other styles

13

Brodbek, Leonie, Jana Kretschmer, Katrin Büsing, Hui Khee Looe, Björn Poppe, and Daniela Poppinga. "Systematic end-to-end testing of multiple target treatments using the modular RUBY phantom." Biomedical Physics & Engineering Express 8, no. 1 (2021): 015018. http://dx.doi.org/10.1088/2057-1976/ac3e37.

Full text

Abstract:

Abstract The RUBY head phantom in combination with the System QA insert MultiMet can be used for simultaneous point dose measurements at an isocentric and two off-axis positions. This study investigates the suitability of the system for systematic integral end-to-end testing of single-isocenter multiple target stereotactic treatments. Several volumetric modulated arc therapy plans were optimized on a planning CT of the phantom positioned in a stereotactic mask on the stereotactic treatment board. The plans were created for three artificial spherical target volumes centred around the measuremen

APA, Harvard, Vancouver, ISO, and other styles

14

Muhammad Sarfraz, Arshad Rabbani, Muhammad Shahzad Manzoor, and Benish Adil. "VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3." Journal of University Medical & Dental College 11, no. 1 (2020): 9–14. http://dx.doi.org/10.37723/jumdc.v11i1.397.

Full text

Abstract:

BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological response (SVR 12). METHODOLOGY: This was a descriptive case study conducted in Liver OPD of Benazir Bhutto Hospital during 01 November 2018 to 30 April 2019 , in which 100 patients of HCV were enrolled, all of them had HCV genotype 3 infection. Every patient was treated with combination of Velpatasvir/Sofosbuvir 100mg/400 mg Once Dai

APA, Harvard, Vancouver, ISO, and other styles

15

Liu, Chun-Jen. "End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B." World Journal of Gastroenterology 10, no. 24 (2004): 3574. http://dx.doi.org/10.3748/wjg.v10.i24.3574.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Winkler, Thomas, Xing Fan, James Cooper, et al. "Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag." Blood 133, no. 24 (2019): 2575–85. http://dx.doi.org/10.1182/blood.2019000478.

Full text

Abstract:

Abstract Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50 to 150 mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of EPAG at a dose of 150 mg could speed and improve response rates. We enrolled 40 patients with rSAA in a study of EPAG 150 mg daily, with a primary end point of response at 24 weeks. Twenty (50%) of 40 patients responded at 24 weeks; 5 (25%) of 20 would have been deemed nonresponders at 12 w

APA, Harvard, Vancouver, ISO, and other styles

17

Smilić, Lj, and Lj Šulović. "RITUXIMAB- MABTHERA - NEW APROACH IN RHEUMAOID ARTHRITIS TREATMENT." Praxis medica 35, no. 1 (2007): 107–9. http://dx.doi.org/10.70949/pramed200701187s.

Full text

Abstract:

&lt;p&gt;Rituximab is a human/mouse chimeric IgG1 monoclonal antibody that specifically targets the CD20 surface antigen expressed on the cell surface of all preplasma cell stages of B-cell differentiation. By binding to CD20, rituximab causes selective B-cell depletion through antibody-dependent and complement-dependent cell lysis and apoptosis. B-cell depletion is believed to disrupt the many B-cell functions that contribute to the pathogenesis of RA. The purpose of this study was to examine the efficacy and safety of RTX an anti-CD20 B cell depleting monoclonal antibody in combinati

APA, Harvard, Vancouver, ISO, and other styles

18

Amichetti, Maurizio, Andrea Bolner, Lucia Busana, et al. "Neoadjuvant Chemotherapy with Vincristine, Bleomycin and Methotrexate Combined with Radiotherapy in Advanced Head and neck Squamous Cell Carcinoma." Tumori Journal 72, no. 3 (1986): 301–6. http://dx.doi.org/10.1177/030089168607200311.

Full text

Abstract:

From September 1980 to August 1981, 25 patients with advanced head and neck squamous cell carcinoma were treated at the Centro Oncologico, Trento, by a chemo-radiotherapeutic combination. The treatment protocol consisted of 4–6 courses of VBM (vincristine, bleomycin and methotrexate) followed by conventional radiotherapy (65 Gy). Only to VBM responders (15 patients) were administered 10 cycles of vincristine-methotrexate. At the end of induction chemotherapy an overall response of 60 % (12 % complete, 48 % partial) was obtained. At the end of radiotherapy the responses were 52.5 % complete and

APA, Harvard, Vancouver, ISO, and other styles

19

Armand, Philippe, Scott Rodig, Vladimir Melnichenko, et al. "Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma." Journal of Clinical Oncology 37, no. 34 (2019): 3291–99. http://dx.doi.org/10.1200/jco.19.01389.

Full text

Abstract:

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade. METHODS In the phase IB KEYNOTE-013 (ClinicalTrials.gov identifier: NCT01953692 ) and phase II KEYNOTE-170 (ClinicalTrials.gov identifier: NCT02576990 ) studies, adults with rrPMBCL received pembrolizumab for up to 2 years or until disea

APA, Harvard, Vancouver, ISO, and other styles

20

Riyal, Hasna, Nilakshi Samaranayake, Priyani Amarathunga, Deepani Munidasa, and Nadira D. Karunaweera. "Histological findings associated with treatment response in cutaneous leishmaniasis: a clinicopathological correlation study." International Journal of Dermatology 62, no. 10 (2023): 1237–47. http://dx.doi.org/10.1111/ijd.16826.

Full text

Abstract:

AbstractBackgroundTreatment responses to cutaneous leishmaniasis (CL) observed in Sri Lanka show variability, ranging from quick healing to delayed or failed responses to routine medication. The determinants of these differences in treatment response are not well defined. This study aimed to identify predictive features of treatment response and outcome in localized CL caused by Leishmania donovani, focusing on both clinical and histopathological findings in the patients.MethodsTissue sections (n = 103) derived from 3 mm punch biopsies of parasitologically confirmed patients were assessed. Pat

APA, Harvard, Vancouver, ISO, and other styles

21

Yen, Cho-Li. "Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders." World Journal of Gastroenterology 11, no. 11 (2005): 1663. http://dx.doi.org/10.3748/wjg.v11.i11.1663.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kostakoglu, Lale, and Grzegorz S. Nowakowski. "End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma." PET Clinics 14, no. 3 (2019): 307–15. http://dx.doi.org/10.1016/j.cpet.2019.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Al-Hamamy, Hayder R., Husam Ali Salman, and Nawar A. Abdulsattar. "Treatment of Plane Warts with a Low-Dose Oral Isotretinoin." ISRN Dermatology 2012 (December 12, 2012): 1–3. http://dx.doi.org/10.5402/2012/163929.

Full text

Abstract:

Objective. To assess the efficacy of a low-dose oral isotretinoin in the treatment of plane warts. Patients and Methods. Thirty-one patients with recalcitrant facial plane warts were enrolled. A cumulative dose of 30 mg/kg for two months of treatment was calculated; this was equal to a mean of 0.5 mg/kg/day. Each patient was seen every two weeks during the treatment period. Response to treatment was either complete or no response. Patients with complete response were followed up monthly for four months to record the relapse rate. Results. Twenty-six patients completed the study; their ages ran

APA, Harvard, Vancouver, ISO, and other styles

24

Sanchorawala, Vaishali, Kathleen T. Finn, Salli Fennessey, Anthony C. Shelton, Jerome B. Zeldis, and David C. Seldin. "Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis." Blood 116, no. 21 (2010): 3022. http://dx.doi.org/10.1182/blood.v116.21.3022.3022.

Full text

Abstract:

Abstract Abstract 3022 The combination of lenalidomide and dexamethasone can produce partial and complete hematologic responses in previously treated patients with AL amyloidosis (Blood 2007; 109: 492–496). Since lenalidomide is primarily excreted unchanged by the kidney, adjustments to the starting dose of lenalidomide are recommended to provide appropriate drug exposure in patients with moderate or severe renal impairment and in patients on dialysis. Based on a pharmacokinetic study in patients with renal impairment due to nonmalignant conditions, lenalidomide starting dose adjustment is rec

APA, Harvard, Vancouver, ISO, and other styles

25

Kim, Youn H., Madeleine Duvic, Erik Obitz, et al. "Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma." Blood 109, no. 11 (2007): 4655–62. http://dx.doi.org/10.1182/blood-2006-12-062877.

Full text

Abstract:

Abstract The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, uncontrolled clinical studies. Patients with treatment refractory CD4+ CTCL (mycosis fungoides [MF], n = 38; Sézary syndrome [SS], n = 9) received 17 weekly infusions of zanolimumab (early-stage patients, 280 and 560 mg; advanced-stage patients, 280 and 980 mg). The primary end point was objective response (OR) as assessed by composite assessment of index lesion disease activity score. Secondary end points included

APA, Harvard, Vancouver, ISO, and other styles

26

Cupit-Link, Margaret, and Sara M. Federico. "Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction." Cancers 15, no. 18 (2023): 4609. http://dx.doi.org/10.3390/cancers15184609.

Full text

Abstract:

Administration of chemoimmunotherapy using concurrent chemotherapy and an anti-GD2 monoclonal antibody (mAb), dinutuximab (DIN), demonstrated efficacy for the treatment of relapsed and refractory neuroblastoma. Chemoimmunotherapy, using a humanized anti-GD2 mAb, demonstrated a signal of activity in a phase 2 study for the treatment of patients with newly diagnosed high-risk neuroblastoma (HRNBL). In this single-institution retrospective study, patients with HRNBL received an Induction chemotherapy regimen plus DIN in all Induction cycles. Toxicity and response data were abstracted from the ele

APA, Harvard, Vancouver, ISO, and other styles

27

Garg, Neha, Rushad Patell, Laura E. Dodge, et al. "Patients' perceptions of treatment benefits and correlation with end-of-life quality markers in advanced malignancy." Journal of Clinical Oncology 40, no. 28_suppl (2022): 188. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.188.

Full text

Abstract:

188 Background: High-quality end-of-life (EOL) care is a recognized goal for modern cancer care delivery. Illness perception is often inaccurate among patients with cancer and may be associated with the quality of EOL care. We surveyed patients receiving palliative cancer-directed therapies to assess associations between accuracy of perceived likelihood of treatment response and recognized EOL quality measures in a cohort of patients with advanced solid malignancies. Methods: Patients and their oncologists were surveyed regarding perceived benefits of palliative cancer-directed therapies. Accu

APA, Harvard, Vancouver, ISO, and other styles

28

Moskowitz, Alison J., Paul A. Hamlin, Miguel-Angel Perales, et al. "Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma." Journal of Clinical Oncology 31, no. 4 (2013): 456–60. http://dx.doi.org/10.1200/jco.2012.45.3308.

Full text

Abstract:

Purpose Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL. Patients and Methods Patients with relapsed and refractory HL who were ineligible for autologous stem-cell transplantation (ASCT), or for whom this treatment failed, received bendamustine 120 mg/m2 as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support. The primary end point was overall response rate (ORR). A secondary end point was referral rate to allogeneic stem-cell transplantation (al

APA, Harvard, Vancouver, ISO, and other styles

29

Kostorov, V. A., T. Yu Semiglazova, and A. V. Pavlysh. "Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer." Medical Council, no. 10 (July 19, 2018): 140–45. http://dx.doi.org/10.21518/2079-701x-2018-10-140-145.

Full text

Abstract:

Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course.

APA, Harvard, Vancouver, ISO, and other styles

30

Ray, Gautam, Subroto Pal, Iqbal Nayyar, and Satyaki Dey. "Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C – a report from Eastern India." Tropical Gastroenterology 28, no. 3 (2007): 109–12. https://doi.org/10.4103/trog_20072803_109.

Full text

Abstract:

Aim: To study the efficacy and tolerability of pegylated interferon alpha 2b and ribavirin therapy in a cohort of chronic hepatitis C patients. Methods: In a prospective, open label, uncontrolled trial pegylated interferon alpha 2b (Viraferon Peg) 1.5 microgram/ kg subcutaneously weekly plus daily ribavirin 800mg for 24 weeks in genotypes 2 & 3 and 1000mg for 48 weeks in genotypes 1 and 4 was administered to 16 patients of chronic hepatitis C. The primary end point was the sustained viral response. Therapy was prolonged by 3 months if the end of therapy response was not attained. Drug dosa

APA, Harvard, Vancouver, ISO, and other styles

31

Albano, Domenico, Francesco Dondi, Giorgio Treglia, et al. "Longitudinal Body Composition Changes Detected by [18F]FDG PET/CT during and after Chemotherapy and Their Prognostic Role in Elderly Hodgkin Lymphoma." Cancers 14, no. 20 (2022): 5147. http://dx.doi.org/10.3390/cancers14205147.

Full text

Abstract:

The aim of this retrospective study was to investigate the longitudinal body changes in terms of muscle and adipose areas and their prognostic role in elderly (>65 years) patients affected by Hodgkin lymphoma (HL). Skeletal muscle area (SMA), skeletal muscle index (SMI), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intramuscular adipose tissue (IMAT), and total dispose tissue (TAT) were measured using the computed tomography (CT) of fluorine-18-fluorodeoxyglucose positron emission tomography/CT ([18F]FDG PET/CT) in 88 patients who undertook baseline, interim (after two

APA, Harvard, Vancouver, ISO, and other styles

32

Rosenberg, Russell, Abby Chen, Teresa Steininger, Wayne Macfadden, and Yves Dauvilliers. "0389 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score." Sleep 45, Supplement_1 (2022): A174—A175. http://dx.doi.org/10.1093/sleep/zsac079.386.

Full text

Abstract:

Abstract Introduction Idiopathic hypersomnia is a debilitating neurologic sleep disorder characterized by excessive daytime sleepiness (EDS), with sleep inertia and prolonged nighttime sleep as key symptoms in many patients. The Epworth Sleepiness Scale (ESS) is an 8-item self-report questionnaire (0–24 score range; higher scores indicate greater EDS). An ESS total score ≤10 is considered normal. The minimum clinically important difference (MCID) for narcolepsy is considered to be a decrease of ≥2 points; the MCID in idiopathic hypersomnia has not been established. This post hoc analysis evalu

APA, Harvard, Vancouver, ISO, and other styles

33

Peymani, Payam, Behzad Yeganeh, Siamak Sabour, et al. "New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)." Canadian Journal of Physiology and Pharmacology 94, no. 6 (2016): 613–19. http://dx.doi.org/10.1139/cjpp-2015-0507.

Full text

Abstract:

Hepatitis C virus (HCV) infection induces autophagy, but the virus assimilates the autophagic response into its own life cycle. Chloroquine (CQ) is an autophagy inhibitor that is clinically used to treat malaria. The aims of this pilot clinical trial were to evaluate the therapeutic potential and short-term safety of CQ in patients with chronic HCV genotype 1, who were unresponsive to a combination of pegylated interferon alpha and ribavirin. Ten non-responders to previous antiviral treatment(s) were randomized to receive either CQ (150 mg daily for 8 weeks) or placebo, and were followed for 4

APA, Harvard, Vancouver, ISO, and other styles

34

NAKAMURA, KAORU, SHIRO BABA, SHIRO SAITO, MASAAKI TACHIBANA, and MASARU MURAI. "High-Intensity Focused Ultrasound Energy for Benign Prostatic Hyperplasia: Clinical Response at 6 Months to Treatment Using Sonablate 200™." Journal of Endourology 11, no. 3 (1997): 197–201. http://dx.doi.org/10.1089/end.1997.11.197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Barnes, Michael E., Alexis L. Gerber, Jill M. Voorhees, and Nathan Huysman. "Stress response of juvenile rainbow trout reared at three densities." Journal of Aquaculture & Marine Biology 12, no. 3 (2023): 292–95. http://dx.doi.org/10.15406/jamb.2023.12.00386.

Full text

Abstract:

High rearing densities (kg of fish per rearing unit volume) can impact fish health and growth. This study evaluated the stress levels (as indicated by blood glucose) and growth of juvenile Shasta strain rainbow trout (Oncorhynchus mykiss) reared at three densities in 1.8-m diameter circular tanks for 111 days. Initial and final rearing densities for each treatment were: low (4.48 and 47.56 kg/m3), medium (5.96 and 60.60 kg/m3), and high (7.49 and 72.42 kg/m3). Throughout the experiment, blood glucose levels from individual fish were not significantly different among the three density treatment

APA, Harvard, Vancouver, ISO, and other styles

36

Osborne, C. K., J. Pippen, S. E. Jones, et al. "Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial." Journal of Clinical Oncology 20, no. 16 (2002): 3386–95. http://dx.doi.org/10.1200/jco.2002.10.058.

Full text

Abstract:

PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment. PATIENTS AND METHODS: In this double-blind, double-dummy, parallel-group study, postmenopausal patients were randomized to receive either an intramuscular injection of fulvestrant 250 mg once monthly or a daily oral dose of anastrozole 1 mg. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), an

APA, Harvard, Vancouver, ISO, and other styles

37

Hogan, T. P., and A. G. Awad. "Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures." Psychological Medicine 22, no. 2 (1992): 347–52. http://dx.doi.org/10.1017/s0033291700030282.

Full text

Abstract:

SYNOPSISThe schizophrenic patient's early psychological response to neuroleptic treatment has been demonstrated to be a significant predictor of treatment response. The validity of the construct of subjective response is evaluated by comparison of two measures. Fifty-five recently admitted and unmedicated schizophrenic patients were randomly allocated to chlorpromazine or haloperidol. Subjective responses at 24 and 48 hours as assessed by two different scales, the Van Putten & May scale and the self-administered Drug Attitude Inventory, were strongly correlated with outcome at three weeks.

APA, Harvard, Vancouver, ISO, and other styles

38

Mason, Tyler B., Kathryn E. Smith, Lisa M. Anderson, et al. "Affective Response to Binge Eating as a Predictor of Treatment Outcomes for Binge-Eating Disorder." Clinical Psychological Science 9, no. 4 (2021): 752–60. http://dx.doi.org/10.1177/2167702620985198.

Full text

Abstract:

In this report, we examined baseline affective response to binge eating as a predictor of binge-eating disorder (BED) treatment outcome. Baseline affective response was defined as (a) each individual’s average net change (i.e., area under the curve [AUC]) of positive affect (PA) or negative affect (NA) before and after binge-eating episodes and (b) slope of PA or NA after binge eating across 7 days of ecological momentary assessment. Adults with BED completed integrative cognitive-affective therapy (ICAT-BED) or cognitive behavioral therapy-guided self-help (CBT-gsh). Individuals with greater

APA, Harvard, Vancouver, ISO, and other styles

39

Diab, Adi, Scott S. Tykodi, Gregory A. Daniels, et al. "Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma." Journal of Clinical Oncology 39, no. 26 (2021): 2914–25. http://dx.doi.org/10.1200/jco.21.00675.

Full text

Abstract:

PURPOSE Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma. METHODS A total of 41 previously untreated patients with stage III/IV melanoma received BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years; 38 were efficacy-evaluable (≥ 1 postbaseline scan). Primary end points were safety and objective response rate (blind

APA, Harvard, Vancouver, ISO, and other styles

40

Salima, Baya, Zlatev Ognyan, Inkov Ivan, Tarif Badr, and Fejjal Nawfal. "Interest of propanolol in the treatment of infantil hemangiomes about a retrospective study of 94 cases." International Journal of Medical Reviews and Case Reports 3, no. 5 (2019): 208–12. https://doi.org/10.5455/IJMRCR.propranolol-treatment-infantil-hemangiomas.

Full text

Abstract:

Infantile hemangioma ( HI ) is the most common children 's vascular tumor . It is a benign tumor with essentially clinical diagnosis. Despite its benign character, treatment is required in many situations. This is a retrospective study of 94 outpatients treated with propranolol and followed in the pediatric plastic surgery department (surgery C) at the Rabat Children's Hospital for a period of 4 years from, 2012 to 2017. The average age of children treated was 3 months, with a female predominance (n = 60, 74%). Tuberous HI was the most common clinical type (n = 68, 70.1%), the single form

APA, Harvard, Vancouver, ISO, and other styles

41

Fabri, Milotka, Milena Bozic, Dragan Delic, Rada Jesic, and Darko Nozic. "Treatment of chronic hepatitis C with pegylated-interferon." Medical review 56, no. 9-10 (2003): 427–30. http://dx.doi.org/10.2298/mpns0310427f.

Full text

Abstract:

Introduction Since the discovery of the hepatitis C virus, the etiology of chronic liver diseases has been revealed in great number of patients. However, the treatment of hepatitis C viral infection still hasn?t been completely resolved. Antiviral and immunomodulatory effects of interferon, and antiviral effect on the nucleoside analogs were efficient only in small number of patients. Discovery of pegylated interferon brings progress in therapeutic success rates. Material and methods Combined therapy with peginterferon alfa-2a (Pegasys) 180mg once a week plus Ribavirin 800mg a day during a 24-

APA, Harvard, Vancouver, ISO, and other styles

42

Steensma, David P., Maria R. Baer, James L. Slack, et al. "Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial." Journal of Clinical Oncology 27, no. 23 (2009): 3842–48. http://dx.doi.org/10.1200/jco.2008.19.6550.

Full text

Abstract:

Purpose Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices. Patients and Methods Patients were treated with decitabine 20 mg/m2 by IV infusion daily for 5 consecutive days every 4 weeks. Eligible patients were ≥ 18 years of ag

APA, Harvard, Vancouver, ISO, and other styles

43

Gunsar, Fulya, Ulus Salih Akarca, Galip Ersoz, et al. "Two-Year Interferon Therapy with Or without Ribavirin in Chronic Delta Hepatitis." Antiviral Therapy 10, no. 6 (2005): 721–26. http://dx.doi.org/10.1177/135965350501000603.

Full text

Abstract:

The only beneficial agent for the treatment of chronic delta hepatitis (CDH) is interferon (IFN). However, there is no consensus on the best dosage or duration of IFN therapy. As ribavirin (RBV) increases the sustained response when added to IFN in chronic hepatitis C, probably because of its immunomodulatory effect, we aimed to investigate the efficacy of 2-year IFN treatment and whether RBV had any additive effect to IFN in CDH. Methods Patients ( n=31) with CDH were randomized with a 1:2 ratio as 10 patients (3 females/7 males, age 39 ±9) receiving IFN monotherapy (9 MU IFN-α2a three times

APA, Harvard, Vancouver, ISO, and other styles

44

Blakeley, Jaishri O., Xiaobu Ye, Dan G. Duda, et al. "Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas." Journal of Clinical Oncology 34, no. 14 (2016): 1669–75. http://dx.doi.org/10.1200/jco.2015.64.3817.

Full text

Abstract:

Purpose Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs. Patients and Methods Bevacizumab 7.5 mg/kg was administered every 3 weeks for 46 weeks, followed by 24 weeks of surveillance after treatment with the drug. The primary end point was hearing response defined by word recognition score (WRS). Secondary end points included toxicity, tolerability, imagin

APA, Harvard, Vancouver, ISO, and other styles

45

Chi, Ping, Li-Xuan Qin, Bastien Nguyen, et al. "Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor." Journal of Clinical Oncology 40, no. 9 (2022): 997–1008. http://dx.doi.org/10.1200/jco.21.02029.

Full text

Abstract:

PURPOSE Dual targeting of the gastrointestinal stromal tumor (GIST) lineage-specific master regulators, ETV1 and KIT, by MEK and KIT inhibitors were synergistic preclinically and may enhance clinical efficacy. This trial was designed to test the efficacy and safety of imatinib plus binimetinib in first-line treatment of GIST. METHODS In this trial ( NCT01991379 ), treatment-naive adult patients with confirmed advanced GISTs received imatinib (400 mg once daily) plus binimetinib (30 mg twice daily), 28-day cycles. The primary end point was RECIST1.1 best objective response rate (ORR; complete r

APA, Harvard, Vancouver, ISO, and other styles

46

De Langen, Joop, Justine Leonie Kuiper, Erik Thunnissen, Sayed MS Hashemi, Kim Monkhorst, and Egbert F. Smit. "Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9042. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9042.

Full text

Abstract:

9042 Background: HER2 expression as well as amplification has been well recognized in tumor biopsies of pts with an EGFR mutation who developed EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumor responses. Methods: Single arm open label phase II study to study the safety and efficacy of paclitaxel-trastuzumab treatment in pts with a sensitizing EGFR mutation who show tumor membrane HER2 expression in a tumor biopsy (immunohistochemistry (IHC) ≥1) after progression on EGFR TKI treatment. Paclitaxel (60 mg/m2) and trastuzumab (first dose 4 mg/kg, therea

APA, Harvard, Vancouver, ISO, and other styles

47

Jagasia, Madan, Miguel-Angel Perales, Mark A. Schroeder, et al. "Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial." Blood 135, no. 20 (2020): 1739–49. http://dx.doi.org/10.1182/blood.2020004823.

Full text

Abstract:

Abstract Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov identifier: NCT02953678), patients aged at least 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive ruxolitinib orally, starting at 5 mg twice daily plus corticosteroids, until treatment failure, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) at day 28; the key secondary end

APA, Harvard, Vancouver, ISO, and other styles

48

Benzoni, Enrico, Franz Cerato, Alessandro Cojutti, et al. "The Predictive Value of Clinical Evaluation of Response to Neoadjuvant Chemoradiation Therapy for Rectal Cancer." Tumori Journal 91, no. 5 (2005): 401–5. http://dx.doi.org/10.1177/030089160509100504.

Full text

Abstract:

Introduction Multimodality therapy has become the standard treatment for patients with locally advanced (T3 and T4) rectal carcinoma. Accurate preoperative staging of the patients with rectal cancer has increased in importance because the selection of patients with transmural rectal cancer (T3 or T4) or node-positive disease leads to a previous nonsurgical neoadjuvant treatment. The purpose of this study was to evaluate the predictive value of the clinical response to neoadjuvant therapy on the basis of pathological results obtained on rectal cancer patients treated by chemoradiotherapy and su

APA, Harvard, Vancouver, ISO, and other styles

49

Bodlaj, Gerd. "Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response." World Journal of Gastroenterology 16, no. 19 (2010): 2407. http://dx.doi.org/10.3748/wjg.v16.i19.2407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Naeem, Abdul, Muhammad Umar, Masood Ahmed, Hamid Sharif, Saima Ambreen, and Ibrar Akbar. "Hemoglobin Level can be a Predictor of End Treatment Response in Chronic Hepatitis C?" American Journal of Gastroenterology 105 (October 2010): S114—S115. http://dx.doi.org/10.14309/00000434-201010001-00309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!